{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:48:24Z","timestamp":1779230904204,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["#005206Q123, 005583Q123"],"award-info":[{"award-number":["#005206Q123, 005583Q123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gastrointestinal (GI) disease in pediatric patients with cystic fibrosis (CF) is a growing concern in the era of improved lung disease; however, the true prevalence of GI diagnoses, medical therapies, and frequency of diagnostic and therapeutic interventions in this population have yet to be explored on a multisystem scale. The aim of the present study was to describe, among pediatric patients with CF (PwCF) compared to a large cohort of healthy controls, the prevalence and types of 1) GI disorders; 2) GI medication use; and 3) GI procedural interventions. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicenter case-control analysis using the TriNetX electronic medical record (EMR) global anonymized data platform. Patients were included if they had an ICD9\/10 diagnosis code and were between the age of zero to \u2264 21 years between January 1st, 2010, and January 1st, 2020. Those with a history of solid organ transplants were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort was comprised of 7,649 patients with a diagnosis of CF (cases) and 22,516,240 patients without CF (controls). The prevalence of any GI disorder was greater in pediatric PwCF compared to those without CF (73% versus &amp;lt;1%). The prevalence of diseases of the biliary tract and pancreas (43% vs. &amp;lt;1%; <jats:italic>p<\/jats:italic>&amp;lt;.0001), hepatic disease (8.8% vs. &amp;lt;1%; <jats:italic>p<\/jats:italic>&amp;lt;.0001), disease of the esophagus to duodenum (34% vs. &amp;lt;1%; <jats:italic>p<\/jats:italic>&amp;lt;.0001), and intestinal disease (43% vs. &amp;lt;1%; <jats:italic>p<\/jats:italic>&amp;lt;.0001) were each significantly greater in PwCF (<jats:italic>p<\/jats:italic>&amp;lt;0.0001). Furthermore, the frequencies of esophagogastroduodenoscopy (EGD), colonoscopy and endoscopic retrograde cholangiopancreatography (ERCP) were significantly higher among PwCF than controls (9.5% vs. &amp;lt;1%; 2.8%% vs. &amp;lt;1%; and 0.3% vs &amp;lt;.001% respectively; <jats:italic>p<\/jats:italic>&amp;lt;0.0001 for all comparisons). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of GI diagnoses, use of GI medications, and frequency of GI procedures are all higher among pediatric patients PwCF. Prospective multicenter studies are warranted to substantiate these findings, further investigate risk factors for GI disorders, and to describe potential changes in GI disorders with novel CF disease-modifying therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgstr.2024.1489876","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:13:23Z","timestamp":1737702803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case\u2013control analysis from the TriNetX EMR-derived global research network real-world dataset"],"prefix":"10.3389","volume":"3","author":[{"given":"Carolena","family":"Trocchia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maua","family":"Mosha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bailey","family":"Hamner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racha","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2016.04.008","article-title":"Gastrointestinal, pancreatic, and hepatobiliary manifestations of cystic fibrosis","volume":"63","author":"Sathe","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"GALAXY Study Group. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2023","journal-title":"J Cyst Fibros;"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000432.PMID:29438119","article-title":"Liver disease in patients with cystic fibrosis","volume":"34","author":"Kamal","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.07.014","article-title":"The impact of liver disease on mortality in cystic fibrosis\u2013a systematic review","volume":"21","author":"Sasame","year":"2022","journal-title":"J Cystic Fibrosis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jcf.2020.12.021","article-title":"Designing the GALAXY study: partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms","volume":"20","author":"Freeman","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.07.002","article-title":"Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY study","volume":"20","author":"Sathe","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE Study group. Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.07.011","article-title":"Cystic fibrosis related gastrointestinal manifestations - moving forward","volume":"20","author":"Birimberg-Schwartz","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.32641\/andespediatr.v92i4.2693","article-title":"Manifestaciones gastrointestinales en fibrosis qu\u00edstica en una poblaci\u00f3n pedi\u00e1trica [Gastrointestinal manifestations of cystic fibrosis in children","volume":"92","author":"Zuloaga","year":"2021","journal-title":"Andes Pediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-021-01225-0","article-title":"Pancreatic, hepatobiliary, and gastrointestinal manifestations of children with cystic fibrosis: A 10-year experience from a tertiary care center in southern India","volume":"41","author":"Thomas","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"NEJM"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bpg.2022.101788","article-title":"Digestive outcomes in cystic fibrosis","volume":"56","author":"Ley","year":"2022","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/ijerph15092020","article-title":"Cystic fibrosis mortality in childhood. Data from european cystic fibrosis society patient registry","volume":"15","author":"Zolin","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.11.004","article-title":"Gastrointestinal disorders in cystic fibrosis","volume":"37","author":"Assis","year":"2016","journal-title":"Clin Chest Med"},{"key":"B17","volume-title":"Cystic fibrosis foundation patient registry 2021 annual data report","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Gupte Gl. Cystic fibrosis associated liver disease in children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i41.6322","article-title":"Focus on gastroesophageal reflux disease in patients with cystic fibrosis","volume":"26","author":"Bongiovanni","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros;"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1489876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:13:25Z","timestamp":1737702805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1489876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":22,"alternative-id":["10.3389\/fgstr.2024.1489876"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2024.1489876","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1489876"}}